

## AGENDA

**7:30 AM NETWORKING BREAKFAST**

**8:00 AM WELCOME**

Jim Palma  
CEO, TargetCancer Foundation

**8:30 AM PATIENT KEYNOTE**

**The Precision Patient: A Case For Seeking Out Innovative, Science-Based Therapy for Patients with Metastatic Cancer**

Allen Chankowsky, Patient Advocate and Author, *On the Other Side of Terminal*

**9:00 AM SESSION 1: ADVANCING INNOVATION IN RARE CANCER TREATMENT**

**MODERATOR: Razelle Kurzrock, MD, Froedtert Medical College of Wisconsin**

**Revolutionizing Rare Cancer Drug Development with Novel Tumour-Agnostic Classifiers and AI Innovations**

Vivek Subbiah, MD  
Chief, Early-Phase Drug Development, Sarah Cannon Research Institute

**N-of-1 Patient Centric Clinical Trials**

Razelle Kurzrock, MD  
Professor of Medicine; Associate Director, Clinical Research  
Founding Director, Michels Rare Cancers Research Laboratories  
Froedtert and Medical College of Wisconsin

**Cellular Therapy in Sarcomas: Current Therapeutic Landscape and Opportunities for Innovation**

Lauren Banks, MD, PhD  
Medical Oncologist, Memorial Sloan Kettering Cancer Center

**Title TBA**

Courtney Johnson, MD  
Division of Clinical Evaluation Oncology, Office of Therapeutic Products, FDA/CBER

**10:45 AM MORNING BREAK**

**11:00 AM SESSION 2: RARE CANCER TARGET SELECTION AND THERAPY IDENTIFICATION**

**MODERATOR: A. John Iafrate, MD, PhD, Massachusetts General Hospital; Harvard Medical School**

**Bench-to-bedside: Using AI and Patient Tissues to Identify Personalized Therapies for Rare and Hard-to-Treat Cancers**

Taran Gujral, PhD  
Associate Professor, Fred Hutchinson Cancer Center

**Speaker To Be Announced**



**12:15 PM NETWORKING LUNCH**

**1:15 PM MOLECULAR TUMOR BOARD**

**TCF-001 TRACK MOLECULAR TUMOR BOARD CASE STUDY PRESENTATION**

Razelle Kurzrock, MD, *Froedtert and Medical College of Wisconsin*

Mina Nikanjam, MD, PhD, *University of California San Diego*

Vivek Subbiah, MD, *Sarah Cannon Research Institute*

Julia Elvin, MD, PhD, *Foundation Medicine*

Aditya Shreenivas, MD, MS, *City of Hope Comprehensive Cancer Center*

Catherine Skefos, MA, MS, CGC, *MD Anderson Cancer Center*

Bicky Thapa, MD, MS, FACP, *Dana-Farber Cancer Institute*

**2:15 PM SESSION 3: CASTING A WIDER NET FOR GERMLINE MUTATIONS  
ACROSS PEDIATRIC CANCERS**

**MODERATOR: Hetal Vig, MS, MGC, CGC, TargetCancer Foundation**

**Universal Germline Testing in Pediatric Cancers: Current Practices and Future Considerations**

Kristin Zelle, MS, CGC

Genetic Counselor, *Children's Hospital of Philadelphia*

**Success Stories and Ethics of Expanded Germline and Cascade Testing in Pediatric Cancer**

Catherine Skefos, MA, MS, CGC

Genetic Counselor, *MD Anderson Cancer Center*

**3:30 PM AFTERNOON BREAK**

**3:45 PM GUIDED DISCUSSION**

**Addressing Barriers to Rare Cancer Clinical Trials and Targeted Treatment Access in the US and Beyond**

Wafik El-Deiry, MD, PhD, FACP

Director, *Legorreta Cancer Center at Brown University*

Chair, *WIN Consortium for Personalized Cancer Medicine*

Jennifer Levin Carter, MD, MPH, MBA

Founder and CEO, *Medzown, Inc.*

**4:25 PM CLOSING DISCUSSION**

**The Power of Personal Experience: Patient and Caregivers As Drivers of Rare Cancer Research**

Michael Casaus

Co-Founder, *CureMEC*

Corrie Painter, PhD

VP External Research & Partnerships, *Precede Biosciences*

President, *Angiosarcoma Awareness*

**5:00 PM COCKTAIL AND DINNER RECEPTION**

# THINK TANK ON ADVANCING PRECISION MEDICINE IN RARE CANCERS

NOVEMBER 20, 2024 | BOSTON, MA

## 2024 STEERING COMMITTEE



**Jennifer Levin Carter, MD, MPH, MBA**  
Founder and CEO, Medzown, Inc.



**A. John Iafrate, MD, PhD**  
Deputy Chair of Pathology, Massachusetts General Hospital  
Professor of Pathology, Harvard Medical School



**Razelle Kurzrock, MD**  
Professor of Medicine, Associate Director, Clinical Research  
Founding Director, Michels Rare Cancers Research Laboratories  
Froedtert and Medical College of Wisconsin  
Principal Investigator, TCF-001 TRACK Study

## THANK YOU TO OUR SPONSORS



TargetCancer Foundation works to advance the development of more effective  
and personalized treatments for people with rare cancers.